

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer emtricitabine with tenofovir tablets.
- **Missed doses** If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

- ▶ **Emtricitabine with tenofovir disoproxil (Non-proprietary)**
Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg | Emtricitabine 200mg / Tenofovir 245mg tablets | 30 tablet [PoM] £355.73 DT = £355.73 (Hospital only) | 30 tablet [PoM] £106.72-£355.73 DT = £355.73
- ▶ **Ictastan** (Actavis UK Ltd)
Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg | Ictastan 200mg/245mg tablets | 30 tablet [PoM] £355.72 DT = £355.73 (Hospital only)
- ▶ **Truvada** (Gilead Sciences International Ltd)
Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg | Truvada 200mg/245mg tablets | 30 tablet [PoM] £355.73 DT = £355.73

Lamivudine**(3TC)**● **INDICATIONS AND DOSE****EPIVIR® ORAL SOLUTION****HIV infection in combination with other antiretroviral drugs**▶ **BY MOUTH**

- ▶ Child 1-2 months: 4 mg/kg twice daily
- ▶ Child 3 months-11 years (body-weight up to 14 kg): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg)
- ▶ Child 3 months-11 years (body-weight 14-20 kg): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 75 mg twice daily, alternatively 150 mg once daily
- ▶ Child 3 months-11 years (body-weight 21-29 kg): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 75 mg daily, dose to be taken in the morning and 150 mg daily, dose to be taken in the evening, alternatively 225 mg once daily
- ▶ Child 3 months-11 years (body-weight 30 kg and above): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 150 mg twice daily, alternatively 300 mg once daily
- ▶ Child 12-17 years: 150 mg twice daily, alternatively 300 mg once daily

EPIVIR® TABLETS**HIV infection in combination with other antiretroviral drugs**▶ **BY MOUTH**

- ▶ Child 1-2 months: 4 mg/kg twice daily
- ▶ Child 3 months-11 years (body-weight up to 14 kg): 4 mg/kg twice daily, alternatively 8 mg/kg once daily
- ▶ Child 3 months-11 years (body-weight 14-20 kg): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 75 mg twice daily, alternatively 150 mg once daily
- ▶ Child 3 months-11 years (body-weight 21-29 kg): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 75 mg daily, dose to be taken in the

- morning and 150 mg daily, dose to be taken in the evening, alternatively 225 mg once daily
- ▶ Child 3 months-11 years (body-weight 30 kg and above): 4 mg/kg twice daily (max. per dose 150 mg), alternatively 8 mg/kg once daily (max. per dose 300 mg), alternatively 150 mg twice daily, alternatively 300 mg once daily
- ▶ Child 12-17 years: 150 mg twice daily, alternatively 300 mg once daily

ZEFFIX®**Chronic hepatitis B infection either with compensated liver disease (with evidence of viral replication and histology of active liver inflammation or fibrosis) when first-line treatments cannot be used, or (in combination with another antiviral drug without cross-resistance to lamivudine) with decompensated liver disease**▶ **BY MOUTH**

- ▶ Child 2-11 years: 3 mg/kg once daily (max. per dose 100 mg), children receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection
- ▶ Child 12-17 years: 100 mg once daily, patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection

● **UNLICENSED USE**

EPIVIR® ORAL SOLUTION Not licensed for use in children under 3 months.

EPIVIR® TABLETS Not licensed for use in children under 3 months.

ZEFFIX® Not licensed for use in children.

- **CAUTIONS** Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine

- **INTERACTIONS** → Appendix 1: lamivudine

● **SIDE-EFFECTS**

- ▶ **Common or very common** Hepatitis aggravated · muscle cramps · myopathy
- ▶ **Rare or very rare** Angioedema
- ▶ **Frequency not known** Abdominal discomfort · malaise · respiratory tract infection · throat complaints

- **BREAST FEEDING** Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.

● **RENAL IMPAIRMENT**

Dose adjustments Reduce dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m²; consult product literature.

- **MONITORING REQUIREMENTS** When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3-6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana and strawberry.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Oral solution

EXCIPIENTS: May contain Sucrose

- ▶ **Eпивir** (ViiV Healthcare UK Ltd)
Lamivudine 10 mg per 1 ml | Epивir 50mg/5ml oral solution | 240 ml [PoM] £39.01

Tablet

- ▶ **Eпивir** (ViiV Healthcare UK Ltd)
Lamivudine 150 mg | Epивir 150mg tablets | 60 tablet [PoM] £143.32 DT = £143.32